-
Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual MeetingDaiichi Sankyo2020-07-24 10:39:26Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting
-
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric CancerDaiichi Sankyo2023-11-10 06:54:49ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer
-
New first-in-class cholesterol-lowering treatment NILEMDO® and its combination with ezetimibe NUSTENDI® approved in EuropeDaiichi Sankyo2020-08-03 09:23:48New first-in-class cholesterol-lowering treatment NILEMDO® and its combination with ezetimibe NUSTENDI®
-
Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary EndpointDaiichi Sankyo2020-01-27 09:31:00Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
